USPTO serial 75456464
Serial No. 75456464
Reviewed by CopyMark Law Group
Reg. 2708236Status 710
- Filing date
- Status date
- Registration date
- Apr 22, 2003
- Examiner
- CHICOSKI, JENNIFER D
- Law office
- POST REGISTRATION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with Serial No. 75456464?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Chuo-ku, Tokyo, JP
Chuo-ku, Tokyo, JP
Chuo-ku, Tokyo, JP
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
JORGE ARCINIEGA
JORGE ARCINIEGA MCDERMOTT WILL & EMERY LLP2049 CENTURY PARK EASTLOS ANGELES, CA 90067-3218UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Agents affecting central nervous system, namely, nervous system stimulants, antipyretic analgesics, anti-epileptics, analeptics, hypnotic sedatives, general anesthetics and anti-dizziness agents; Agents affecting peripheral nervous system, namely, local anesthetics, skeletal muscle relaxants, anhydrotics, autonomics, spasmolytics and diaphoretics; Agents affecting sensory organs, namely, ophthalmic use agents and otorhinolar use agents; Antiallergic agents, namely, anti-histamines and stimulation therapy agents; Cardiovascular agents, namely, cardiotonics, antihypertensive agents, vasoconstrictive agents, vasosupportive agents, cerebral hemorrhage prophylactics, antiarrhythmic agents and diuretics; Agents affecting respiratory organs, namely, respiratory stimulants, anti-cough drops and anti-tussive expectorants; Agents affecting digestive organs, namely, gastrointestinal cleaning agents, clysters, enemas, purgatives, evacuants, stomachics/digestives, agents for oral use, namely, medicare mouthwash, mouth cavity cleanser, emetics, medicines for dental purposes, namely, procaine anesthetics and nitrous oxide, antacids, antidiarrheals, anti-emetics, castor oil for medical purposes, tooth prophylactics and choleretics; Hormones for medical purposes, namely, thyroid/parathyroid hormone preparations, mixed hormone preparations, estrogens, pancreatic hormone preparations, salivary gland hormone preparations, androgens, pituitary hormone preparations and adrenal hormone preparations; Urogenital or anal treatment agents, namely, oxytocics, antihemorrhoidals, emmenagogues, urinary disinfectants and contraceptives; Dermatological preparations, namely, dermatics for purulence, anti-dermoinfectives, skin disinfectants, astringents for medical purposes, cataplasms, anti-inflammatory agents, analgesics, antipruritic agents, medicated handwashes, hair remedies, namely, hair growth stimulants, medicated baby oils, medicated baby powders and medicated bath preparations; Vitamin preparations, namely, cod-liver oil drops, mixed vitamin preparations, vitamin A preparations, vitamin C preparations, vitamin D preparations, vitamin B preparations and multi-vitamin preparations; Amino acid preparations, namely, threonine, tryptophane, methionine and lysine for use as dietary supplements; Nutrients, tonics and denaturizers, namely, royal jelly for medical purposes, calcium preparations, chondroitin preparations, food enriching preparations, organotherapy preparations, protein/amino acid preparations, saccharide preparations, mineral preparations, medicinal alcoholic beverages and organic acid preparations, all for use as dietary supplements; Agents for blood, namely, anticoagulants, blood substitutes, blood plasma and hemostatics; Metabolic agents, namely, antidotes, enzyme preparations, lactagogues, lipotropic factor preparations and habitual intoxication treating agents; Cellular function activating agents, namely, chlorophyll preparations and dyes; Tumor suppressing agents, namely, anti-cancer preparations and anti-sarcoma preparations; Agents for treating physically caused lesions, namely, heatstroke treating agents and radiation sickness treating agents; Agents for treating chemically caused lesions, namely, anti-chlorine poisoning preparations, anti-arsenic poisoning preparations and anti-benzol poisoning preparations; Antibiotic preparations, namely, erythromycin preparations, chloramphenicol preparations, colistin-polymixin preparations, salkomycin and its preparations, streptomycin and its preparations, thiolutin preparations, tetracycline and its preparations, trichomycin and its preparations, mixed antibiotic preparations and penicillin and its preparations; Chemotherapeutic agents, namely, antisyphilitics, antituberculotic agents, sulfonamide preparations and antileprosy agents; Biological preparations for medical purposes, namely, antitoxic serums, antitoxins, clinical or medical diagnostic aids for biological tests, namely, toxoids toxins and vaccines; Parasiticides, namely, anthelmintics, parasiticides and antiprotozoals for use in the treatment of humans, pets and livestock; Agents for dispensing use, namely, corrigent in the nature of offensive smell and taste correctives; Diagnostic preparations, namely, x-ray contrast media, diagnostic reagents and diagnostic media for medical or clinical use; Isotope labelling substances for treatment or diagnosis; Narcotics, namely, opium alkaloid preparations, synthetic narcotics and coca alkaloid preparations; Crude drugs, charred drugs and Moxa for use in the treatment of pain relief; Veterinary preparations, namely, mosquito-repellent incenses; general purpose germicides, fungicides, rodenticides, rat poison, insecticides, pesticides, fumigants, and herbicides all for domestic, agricultural and horticultural uses; deodorants not for personal use; insect repellents and mothproofing preparations; antiseptics; dental impression materials; medical oiled papers; gauze for dressing wounds; unit dose capsules sold empty for pharmaceutical use; ear bandages; menstruation bandages; menstruation tampons; menstruation sanitary napkins and pads; menstruation panties and knickers; absorbent cotton for medical use; medical adhesive plaster; surgical bandages for dressing wounds; collodion, namely, a yellow syrup liquid used for fixing bandages or covering an affected part; incontinence diapers and napkins for incontinents; semen for artificial insemination; powdered milk for babies, lactose milk sugar for use as a dietary supplement; fly catching paper; and mothproofing paper | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 29, 2013 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| Dec 3, 2008 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Nov 24, 2008 | PLGL | ASSIGNED TO PARALEGAL | — |
| Nov 21, 2008 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| May 15, 2008 | CFIT | CASE FILE IN TICRS | — |
| Apr 22, 2003 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 28, 2003 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2003 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 15, 2002 | PAPER RECEIVED | — | |
| Jul 8, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 8, 2002 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 8, 2002 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Mar 11, 2002 | 44DD | SEC. 44(D) CLAIM DELETED | — |
| Feb 6, 2002 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Oct 11, 2001 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 1, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 18, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 19, 2000 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 8, 2000 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 23, 2000 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 17, 1999 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| May 14, 1999 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Apr 5, 1999 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 11, 1998 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 18, 1998 | DOCK | ASSIGNED TO EXAMINER | — |